Skip to main content

Table 9 Incremental cost-effectiveness ratio of PEMF vs. standard treatment for acute scaphoid fractures for working patients only

From: Functional outcome and cost-effectiveness of pulsed electromagnetic fields in the treatment of acute scaphoid fractures: a cost-utility analysis

  Costs* QALY ICER
Group A (Active) €3305 0.8474  
Group B (Placebo) €2634 0.8415  
Increment €670 0.0059 113559
  1. *Costs are denoted in Euro.
  2. QALY, quality adjusted life year; ICER, incremental cost-effectiveness ratio.